CMIC to bring Orphan Europe's Normosang to Japan
This article was originally published in Scrip
Executive Summary
The Recordatisubsidiary Orphan Europe has licensed its porphyria therapy Normosang (human hemin) to CMIC for development and commercialisation in Japan. Financial terms were not disclosed.